Retatrutide

CAS No.: 2381089-83-2

Retatrutide Chemical Structure

Molecular formula: C₂₂₁H₃₄₂N₄₆O₆₈

Molecular weight: 4731. 33

Patent period: Compound: 2026 Composition: 2029

Dositive specifications: –

Injection (type II diabetes, OZEMPIC) : —

Oral tablets: —

Injection : —

Get in touch Download

Products are for laboratory research use only. Not for human use. We do not sell to patients.

Biological Activity

Retatrutide Retarutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR) , glucose-dependent insulin-promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) . It is a peptide composed of about 40 amino acids and contains double targets in its sequence. Retarutide inhibited human GCGR, GIPR and GLP-1R with EC50 values of 5. 79, 0. 0643 and 0. 775nM, respectively. Retarutide can be used for obesity research.

Chemical Properties

ACTIONS	—
CAS NO.	2381089-83-2
FORMULA	C₂₂₁H₃₄₂N₄₆O₆₈
M. WT	4731. 33
PURITY	> 98%
SYNONYMS	LY3437943
STORAGE	—

Online Inquiry

Obesity

The number of global obesity in 2020 reached 1. 211 billion, an increase of 58 million people from 2019, an increase of 5. 04% year -on -year.In 2020, the number of obesity in China reached 220 million people, an increase of 1. 10 billion from 2019, an increase of 4. 77%year -on -year.

Other Drug Peptide More+

Tirzepatide new

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined .
Semaglutide new

Semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC) , in humans as the human relevance of semaglutide-induced rodent thyroid Ccell tumors has not been determined.
Retatrutide new

Retarutide (LY3437943) is a triple agonist peptide of glucagon receptor (GCGR) , glucose-dependent insulin-promoting peptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) . It is a peptide composed of about 40 amino acids and contains double targets in its sequence. Retarutide inhibited human GCGR, GIPR and GLP-1R with EC50 values of 5. 79, 0. 0643 and 0. 775nM, respectively. Retarutide can be used for obesity research.
Cagrilintide new

Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.

Product Catalog

Retatrutide

GUIZHOU MTPEPTIDES BIOTECHNOLOGY CO., LTD